Precision BioSciences, Inc. - DTIL STOCK NEWS

Precision BioSciences has announced the appointment of Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific Advisory Board. Both are esteemed clinicians in the field of hepatitis. This move aims to bolster the company's expertise as it prepares to submit IND and/or CTA applications for its PBGENE-HBV program in the second half of 2024. The additions aim to enhance the development and potential approval of PBGENE-HBV, which utilizes Precision’s proprietary ARCUS gene-editing platform. The advisory board will now include three key experts: Dr. Sulkowski, Dr. Feld, and Dr. Raymond Schinazi.

Precision BioSciences (Nasdaq: DTIL) has announced promising preclinical safety data for its PBGENE-HBV candidate at the European Association for the Study of the Liver Congress. The data demonstrate that PBGENE-HBV can specifically target and cut HBV DNA without affecting the human genome, showing high specificity and no detectable off-target editing. Additionally, non-human primate studies indicated that PBGENE-HBV is well-tolerated, even with multiple administrations. This supports the candidate's potential as a curative treatment for chronic hepatitis B. Precision BioSciences aims to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-HBV in 2024.

Precision BioSciences (Nasdaq: DTIL) will participate in two significant investor conferences in June 2024. The company, known for its ARCUS® gene editing platform, will be present at the Jefferies Global Healthcare Conference on June 5, 2024, from 1:30 pm to 1:55 pm ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, from 10:00 am to 10:35 am ET. Both events will feature fireside chats with management. Live webcasts will be available on Precision BioSciences' website, with replays accessible for 30 days post-event.

On May 13, 2024, Precision BioSciences announced the grant of inducement awards to new employees, approved by the Compensation Committee of its Board of Directors. These awards, given under the 2021 Employment Inducement Incentive Award Plan, include stock options for 18,511 shares and 17,124 restricted stock units (RSUs). Each stock option has an exercise price of $11.50 per share, a 10-year term, and vests over four years. The RSUs vest annually over three years. These awards are intended to attract new talent to the company.

Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.

Precision BioSciences, Inc. announced a private placement where the company will issue and sell 25,000 shares of common stock to its senior leadership team, including the CEO, at a price of $12.00 per share, totaling $300,000. The Private Placement is set to close on May 8, 2024, with the net proceeds intended for research and development initiatives.

Precision BioSciences, Inc. (Nasdaq: DTIL) will report its first-quarter financial results on May 13, 2024. The company utilizes its ARCUS® platform for gene editing therapies, including elimination, insertion, and excision.

Precision BioSciences, Inc. (Nasdaq: DTIL) announced that its partner iECURE has received FDA Fast Track designation for ECUR-506 to treat Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency. The Fast Track designation expedites the review process for therapeutics addressing unmet medical needs. ECUR-506 also received Rare Pediatric Disease and Orphan Drug designations.

iECURE, Inc. has received Fast Track designation from the FDA for ECUR-506, an in vivo gene insertion program to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The designation helps expedite the review process for therapies addressing unmet medical needs. The company's OTC-HOPE study is open for enrollment in the UK, with sites in the US and Australia to follow, focusing on safety, efficacy, and other endpoints.